Managing Treatment-Resistant Depression
Road to Novel Therapeutics
- 1st Edition - March 31, 2022
- Imprint: Academic Press
- Editors: Joao L. de Quevedo, Patricio Riva-Posse, William V. Bobo
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 4 0 6 7 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 4 0 6 8 - 7
Managing Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurob… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteManaging Treatment-Resistant Depression: Road to Novel Therapeutics defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. In addition, staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting the use of psychotherapies and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD.
- Defines Treatment-Resistant Depression and Staging Treatment Intensity
- Includes Treatment-Resistant Depression options for children, adolescents, geriatrics, during pregnancy, and during post-partum and menopause transitions
- Discusses the use of Ketamine and Esketamine for treatment-resistant depression
Advanced students and researchers in neuroscience, psychology, medicine, health sciences, and pharmacology
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1: Defining treatment-resistant depression, difficult-to-treat depression, and staging treatment intensity
- Abstract
- Introduction
- Treatment-resistant depression
- Difficult-to-treat depression
- Conclusions
- References
- Chapter 2: Clinical and epidemiological predictors of treatment-resistant depression
- Abstract
- Introduction
- Clinical predictors
- Epidemiological predictors
- Discussion
- References
- Chapter 3: The economic burden of treatment-resistant depression: Cost-of-illness perspective
- Abstract
- Introduction
- Economic burden from a cost-of-illness perspective
- The cost of treatment-resistant depression
- Discussion
- Conclusion
- References
- Chapter 4: The neurobiology of treatment-resistant depression
- Abstract
- Introduction
- Why do people get depressed?
- How do antidepressant treatments work?
- Why do antidepressants fail?
- Why is ketamine different?
- Conclusions
- References
- Chapter 5: Modeling treatment-resistant depression in the preclinical setting
- Abstract
- Introduction
- Common mechanisms of antidepressant response in depression
- Studying antidepressant response in preclinical models
- Animal models
- Rodent animal models
- Other animal models of depression
- Cellular models
- Induced pluripotent stem cells
- Cocultured cellular models
- High-throughput peripheral blood mononuclear cell assays
- Multiscale reverse translation modeling of TRD
- Conclusions
- References
- Chapter 6: Treatment algorithms for treatment-resistant depression
- Abstract
- Introduction
- Early treatment algorithms: GAP, TMAP, and STAR*D
- Subsequent treatment algorithms: 2015–20
- The benefits of treatment algorithms
- Cost efficacy of algorithms
- Algorithm development
- Implementing algorithms in clinical practice
- The future of algorithms
- Conclusion
- References
- Chapter 7: Tools to aid precision treatments to prevent or manage treatment-resistant depression (TRD): Pharmacogenomics, machine learning, and artificial intelligence
- Abstract
- Introduction
- Brief history of pharmacogenomic tests and algorithms for clinical use
- Evidence for pharmacogenomic testing in clinical practice
- PGx economic studies
- Algorithms for medication guidance
- Machine learning for medication guidance
- AI for medication guidance
- Genome-wide association studies and polygenic risk scores (PRS) for diagnosis and medication guidance
- A note on black box algorithms
- Future directions for PGx and algorithm testing
- References
- Further reading
- Chapter 8: Tricyclic antidepressants for treatment-resistant depression
- Abstract
- Introduction
- Pharmacological properties
- Indications
- Clinical studies in people with treatment-resistant depression
- Adverse effects and toxicology
- Drug interactions
- Clinical use
- Summary
- Additional resources
- References
- Chapter 9: Monoamine oxidase inhibitors for treatment-resistant depression
- Abstract
- Introduction
- Pharmacological properties
- Indications
- Clinical studies in people with treatment-resistant depression
- Adverse effects and toxicology
- Interactions
- Clinical use
- Summary
- Additional resources
- References
- Chapter 10: Switching antidepressants in patients with treatment-resistant depression
- Abstract
- Introduction
- Switching antidepressant and TRD definition
- Switching within the same class or switching across classes?
- Is switching better than continuation of the same antidepressant?
- Practical and clinical issues in switching antidepressants
- Choice of second step antidepressant
- Conclusions
- References
- Chapter 11: Adjunctive strategies for treatment-resistant depression
- Abstract
- Overview
- General principles of adjunctive therapy
- Preferred options for adjunctive therapy
- Other options for adjunctive therapy
- Notable failures, disappointments, and near misses
- Summary
- References
- Chapter 12: Combining antidepressants to address treatment-resistant depression
- Abstract
- Charles B. Nemeroff, M.D., Ph.D.
- Julie Farrington, M.D.
- Sussann Kotara, M.D.
- Brief overview of antidepressants
- References
- Chapter 13: Ketamine/esketamine for treatment-resistant depression
- Abstract
- Introduction
- History
- Efficacy
- Safety
- Implementation
- Conclusion
- References
- Chapter 14: Psychedelic agents for treatment-resistant depression
- Abstract
- Acknowledgments
- Introduction
- Chemistry
- Pharmacokinetics
- Mechanisms of action
- Clinical studies
- Adverse effects and toxicology
- Drug interactions
- Summary and future directions
- References
- Chapter 15: Inflammation and treatment resistance: Mechanisms and treatment implications
- Abstract
- Introduction
- Foundation for the hypothesis of inflammation’s role in depression
- Clinical predictors of treatment resistance and inflammation
- Mechanisms by which inflammation affects antidepressant treatment response
- Impact of inflammation on neurocircuits
- Therapeutic targets addressing TRD and inflammation
- Future directions
- References
- Chapter 16: Opioid agents for treatment-resistant depression
- Abstract
- Introduction
- Opioid agents and their potential in treatment-resistant depression
- Opioid agents: Mechanisms of action, pharmacokinetics and clinical studies
- Summary and future directions
- References
- Chapter 17: Transcranial magnetic stimulation for treatment-resistant depression
- Abstract
- Introduction
- Historical overview
- Proposed mechanisms: How does TMS work?
- Parameters, response and remission rates, and durability
- Effect on treatment-resistant bipolar depression
- Potential biomarkers
- Optimal stimulation parameters
- Future directions and perspectives
- References
- Chapter 18: tDCS for treatment-resistant depression
- Abstract
- Introduction
- History and development
- Mechanisms of action
- Clinical efficacy of tDCS for TRD patients
- Adverse effects
- Adverse effects in depression trials
- Summary and future directions
- Conclusions
- References
- Further reading
- Chapter 19: ECT for treatment-resistant depression
- Abstract
- Introduction
- ECT basics
- History and development
- Mechanisms of action
- Clinical studies
- Direct comparison to other treatments
- Bipolar depression
- Depression with psychotic features
- Suicidality
- Special populations
- Maintenance ECT (M-ECT)
- Safety and adverse effects of ECT
- Future directions
- Summary
- References
- Chapter 20: MST for treatment-resistant depression
- Abstract
- Introduction
- History and development
- Clinical studies
- Adverse effects and interactions
- Mechanism of action
- Other indications
- Conclusion
- References
- Chapter 21: VNS for treatment-resistant depression
- Abstract
- History
- The VNS device and its mechanism of action
- Indications
- Clinical studies
- Adverse effects
- Interactions
- Transcutaneous vagus nerve stimulation
- Conclusion
- References
- Chapter 22: Deep brain stimulation for treatment-resistant depression
- Abstract
- Introduction
- Targets for DBS in treatment-resistant depression
- Conclusions
- References
- Chapter 23: Other neurosurgical interventions for treatment-resistant depression
- Abstract
- Acknowledgments
- Introduction
- PCS: The over simplification of the functional neuroanatomy of mood regulation may lead to missed opportunities in treatment development
- Psychiatric neurosurgery
- Future directions
- References
- Chapter 24: Treatment-resistant psychotic depression
- Abstract
- Introduction
- Evidence-based treatment of psychotic depression
- Options to consider for treatment-resistant psychotic depression
- Summary
- References
- Chapter 25: Evidence-based psychotherapy for treatment-resistant depression
- Abstract
- Introduction
- Effectiveness of psychotherapy for depression
- Effectiveness of psychotherapy for TRD
- Psychotherapy methods for TRD
- Conclusion
- References
- Chapter 26: Treatment-resistant bipolar depression
- Abstract
- Introduction
- Variables associated with treatment resistance in bipolar depression
- Management of treatment-resistant bipolar depression
- Interventions for treatment-resistant bipolar depression
- Conclusions
- References
- Chapter 27: Treatment-resistant depression in children and adolescents
- Abstract
- Introduction
- Depression in youth
- Treatment-resistant depression studies
- Antidepressant studies for acute treatment
- Psychotherapy studies for acute treatment
- Complementary alternative medicine
- Combination treatment
- Factors associated with treatment nonresponse
- Conclusion
- References
- Chapter 28: Treatment-resistant depression in geriatrics
- Abstract
- Introduction
- Epidemiology
- Pathophysiology
- Clinical presentation
- Current treatment options
- Future directions
- References
- Chapter 29: Identification and management of anxious depression in patients with treatment-resistant depression
- Abstract
- Part I: Identification
- Part II: Management
- Part III: Clinical summary
- References
- Part I references
- Psychopharmacology references
- Ketamine references
- ECT references
- TMS references
- Psychotherapy references
- Psychedelics references
- VNS references
- DBS references
- Clinical summary references
- Chapter 30: Managing treatment-resistant depression with comorbid personality disorders
- Abstract
- Personality disorders in DSM-5
- The relationship between personality disorders and depression
- Assessment of comorbid personality and depressive disorders
- The impact of personality disorders on functioning and treatment outcome in patients with MDD
- Borderline personality disorder and depression
- Narcissistic personality disorder and depression
- Alternative, personality-derived models of TRD
- Clinical summary
- Appendix
- References
- Chapter 31: Managing treatment-resistant depression with comorbid substance use disorders
- Abstract
- Introduction
- Alcohol use disorder and major depressive disorder
- Opioid use disorder and major depressive disorder
- Stimulant (cocaine and methamphetamine) use disorder and major depressive disorder
- Summary of the chapter: Practical considerations
- References
- Chapter 32: Managing treatment-resistant depression in the setting of chronic pain
- Abstract
- Definition and measurement of chronic pain disorders
- The McGill Pain Questionnaire and the Brief Pain Inventory
- Summary of recommendations for assessment practices in comorbid pain and depression scenarios
- How common is depression in pain patients?
- How common is pain in depression patients?
- What is the impact of pain and depression comorbidity, in terms of outcomes either for depression or for pain?
- Approaches to treatment of comorbid pain and depression
- Medication treatment of comorbid pain and depression
- Overall results from antidepressants
- Key antidepressants for special consideration
- Conclusion
- References
- Chapter 33: Inhaled gases for treatment-resistant major depression
- Abstract
- Acknowledgment
- Introduction
- Nitrous oxide
- Isoflurane
- Xenon
- The use of inhalants in complimentary medicine: Aromatherapy
- References
- Chapter 34: Drugs under investigation for treatment-resistant depression
- Abstract
- Medications targeting the hypothalamic–pituitary–adrenal (HPA) axis
- Medication targeting the melatonergic system
- Medications targeting the glutamatergic system
- Atypical antipsychotics
- Other drugs
- Conclusions
- References
- Chapter 35: Chronotherapeutics for treatment-resistant depression
- Abstract
- Introduction
- Light therapy
- Sleep deprivation therapy and combined chronotherapies
- Conclusions
- References
- Chapter 36: Managing treatment resistant depression in primary care settings
- Abstract
- Scope of problem
- Challenges of managing TRD in primary care settings
- Collaborative care for management of depression in primary care (Fig. 36.1)
- Components of collaborative care for depression
- Advancing treatment in primary care settings
- Clinical summary (Table 36.1)
- References
- Chapter 37: Treatment-resistant depression in pregnancy, the postpartum period, and transition to menopause
- Abstract
- Introduction
- Unipolar peripartum depression
- Pharmacologic treatment of unipolar peripartum depression
- Peripartum bipolar depression
- Depression during the transition to menopause
- References
- Chapter 38: Lifestyle interventions for treatment-resistant depression
- Abstract
- Introduction
- Diet and nutrition
- Probiotics
- Mindfulness
- Mindful movement
- Exercise
- Acupuncture
- Common mechanisms of action of lifestyle modifications
- References
- Chapter 39: Managing the risk of suicide in people with treatment-resistant depression
- Abstract
- Introduction
- Terms and definitions
- Suicide prevalence
- Suicide risk factors
- Alternative methods for suicide prediction
- Suicide risk in TRD
- Treatment of suicide in TRD
- Conclusions and future directions
- References
- Chapter 40: Maintaining motivation and preserving the therapeutic alliance as tools to overcome treatment-resistant depression
- Abstract
- Understanding the therapeutic Alliance
- Relationship between therapeutic alliance and treatment outcome
- Techniques to improve therapeutic alliance and enhance motivation
- Therapeutic alliance in telehealth and other technology-based interventions
- Clinical summary
- Disclaimers
- References
- Index
- Edition: 1
- Published: March 31, 2022
- No. of pages (Paperback): 612
- No. of pages (eBook): 612
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128240670
- eBook ISBN: 9780128240687
JQ
Joao L. de Quevedo
Dr. João Luciano de Quevedo, MD, PhD, is a Professor of Psychiatry at the McGovern Medical School, the University of Texas Health Science Center at Houston, where he is the Vice-Chair for Faculty Development and Outreach, Director of the Translational Psychiatry Program, and Director of the Treatment-Resistant Depression Clinic. Before moving to Houston, he was a Dean at the University of Southern Santa Catarina Medical School, Criciúma, SC, Brazil, where he is still an Adjunct Professor of Psychiatry. He is also Editor-in-Chief of the Brazilian Journal of Psychiatry and Director of the Continuous Medical Education Program in Psychiatry (PROPSIQ) of the Brazilian Psychiatric Association. Dr. Quevedo’s research interest is neurobiology of psychiatric disorders, particularly mood disorders, and he is a specialist in both unipolar and bipolar treatment–resistant depression. He is author of nearly 600 publications and 10 scientific books.
Affiliations and expertise
Professor of Psychiatry at the McGovern Medical School, The University of Texas Health Science Center at Houston, TX, USAPR
Patricio Riva-Posse
Dr. Patricio Riva-Posse, MD is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine. After completing his training in Neurology and in Psychiatry, he has focused his clinical and research work in the field of treatment resistant mood disorders. He is the Director of the Treatment Resistant Depression Clinic, and Director of Neuromodulation Services. He conducts research in invasive and non-invasive neuromodulation as well as novel pharmacological approaches. He is an investigator in NIH-funded project studying subcallosal cingulate deep brain stimulation. Born in Argentina, he earned his Medical Doctor degree from the Universidad de Buenos Aires.
Affiliations and expertise
Emory University, Atlanta, GA, USAWB
William V. Bobo
Dr. William V. Bobo, M.D., M.P.H., is Professor of Psychiatry at the Mayo Clinic Alix School of Medicine and Chair, Department of Psychiatry & Psychology at Mayo Florida, where he also serves as the Medical Director for Leadership Development. His clinical and research interests are focused on the treatment of patients with refractory mood disorders and on examining and predicting the clinical effects — both beneficial and harmful--of medications used to treat people with severe mood disorders. He lives with his wife in Jacksonville, Florida.
Affiliations and expertise
Mayo Clinic, Jacksonville, FL, USARead Managing Treatment-Resistant Depression on ScienceDirect